WAPL-Dependent Repair of Damaged DNA Replication Forks Underlies Oncogene-Induced Loss of Sister Chromatid Cohesion.

Developmental cell (2020-02-23)
Bente Benedict, Janne J M van Schie, Anneke B Oostra, Jesper A Balk, Rob M F Wolthuis, Hein Te Riele, Job de Lange
RESUMEN

Premature loss of sister chromatid cohesion at metaphase is a diagnostic marker for different cohesinopathies. Here, we report that metaphase spreads of many cancer cell lines also show premature loss of sister chromatid cohesion. Cohesion loss occurs independently of mutations in cohesion factors including SA2, a cohesin subunit frequently inactivated in cancer. In untransformed cells, induction of DNA replication stress by activation of oncogenes or inhibition of DNA replication is sufficient to trigger sister chromatid cohesion loss. Importantly, cell growth under conditions of replication stress requires the cohesin remover WAPL. WAPL promotes rapid RAD51-dependent repair and restart of broken replication forks. We propose that active removal of cohesin allows cancer cells to overcome DNA replication stress. This leads to oncogene-induced cohesion loss from newly synthesized sister chromatids that may contribute to genomic instability and likely represents a targetable cancer cell vulnerability.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Nocodazole, ≥99% (TLC), powder
Sigma-Aldrich
Etoposide, synthetic, 98.0-105.0%, powder
Sigma-Aldrich
(+)-Sodium L-ascorbate, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
(S)-(+)-Camptothecin, ≥90% (HPLC), powder
Sigma-Aldrich
5-Chloro-2′-deoxyuridine, thymidine analog
Sigma-Aldrich
6-Carboxyfluorescein, ~97% (HPLC)
Sigma-Aldrich
Mirin, ≥98% (HPLC), powder
Sigma-Aldrich
RAD51 Inhibitor B02, ≥98% (HPLC)
Sigma-Aldrich
5′-Bromo-2′-hydroxyacetophenone, 98%

Redes sociales

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

Investigación. Desarrollo. Producción.

Somos un proveedor líder para la industria de Ciencias de la Vida con soluciones y servicios para investigación, desarrollo y producción biotecnológicos, y para desarrollo y producción de tratamientos farmacéuticos

© 2021 Merck KGaA, Darmstadt, Alemania y/o sus filiales. Todos los derechos reservados.

Queda estrictamente prohibida la reproducción sin permiso de cualquiera de los materiales de la página web.